Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02390167 · ClinicalTrials.gov registry record · NA

Evaluation of a Ascensia ONYX NEXT Investigational Blood Glucose Monitoring System

A NA study of Diabetes, sponsored by Ascensia Diabetes Care.

Completed
Registry status
NA
Development phase
376
Enrollment target
2
Study locations

NCT02390167 is a NA study of Diabetes that has completed, run by Ascensia Diabetes Care. The registered enrollment target is 376 participants, below the 3,027-participant average among 338 other Diabetes trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02390167, a NA study of Diabetes, has completed, sponsored by Ascensia Diabetes Care.

COMPLETED
Registry status
NA
Development phase
376 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study was to determine if untrained subjects with diabetes and without diabetes could operate the Investigational Blood Glucose Monitoring System (BGMS) and obtain valid glucose results.

Conditions Studied

Interventions

  • DEVICE ONYX NEXT BGMS

Study Locations (2)

California

  • AMCR Institute - Escondido
  • Diablo Clinical Research - Walnut Creek

Trial Details

FieldValue
Enrollment Target 376 participants
Start Date 2015-03
Est. Completion 2015-04
Phase NA

Sponsor

Ascensia Diabetes Care

42 total trials

What the Registry Record Tells You About NCT02390167

The ClinicalTrials.gov registry entry for NCT02390167 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 376 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,027-participant average among 338 other Diabetes trials with a reported enrollment target (88% lower). The listed sponsor is Ascensia Diabetes Care, which has 42 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which ONYX NEXT BGMS is the first listed.

NCT02390167 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT02390167 about?

NCT02390167 is a clinical study titled "Evaluation of a Ascensia ONYX NEXT Investigational Blood Glucose Monitoring System". The purpose of this study was to determine if untrained subjects with diabetes and without diabetes could operate the Investigational Blood Glucose Monitoring System (BGMS) and obtain valid glucose results.

What is the current status of trial NCT02390167?

This trial is currently completed. It is a NA study. The enrollment target is 376 participants. The study started on 2015-03. Estimated completion is 2015-04.

What conditions does trial NCT02390167 study?

This clinical trial studies the following conditions: Diabetes.

What interventions are being tested in trial NCT02390167?

The interventions under investigation include: ONYX NEXT BGMS (DEVICE).

Who is sponsoring clinical trial NCT02390167?

This trial is sponsored by Ascensia Diabetes Care, which has 42 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02390167 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.